Literature DB >> 17286245

The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging.

Susan Brutkiewicz1, Marc Mendonca, Keith Stantz, Kathleen Comerford, Robert Bigsby, Gary Hutchins, Mark Goebl, Maureen Harrington.   

Abstract

In vivo bioluminescence imaging is becoming a very important tool for the study of a variety of cellular and molecular events or disease processes in living systems. In vivo bioluminescence imaging is based on the detection of light emitted from within an animal. The light is generated as a product of the luciferase-luciferin reaction taking place in a cell. In this study, we implanted mice with tumour cells expressing either a high or a low level of luciferase. In vivo bioluminescence imaging was used to follow tumour progression. Repeated luciferin injection and imaging of high and low luciferase-expressing tumours was performed. While low luciferase-expressing tumours grew similarly to vector controls, growth of the high luciferase-expressing tumours was severely inhibited. The observation that a high level of luciferase expression will inhibit tumour cell growth when an animal is subjected to serial in vivo bioluminescence imaging is potentially an important factor in designing these types of studies. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17286245     DOI: 10.1002/bio.953

Source DB:  PubMed          Journal:  Luminescence        ISSN: 1522-7235            Impact factor:   2.464


  14 in total

1.  An enhanced chimeric firefly luciferase-inspired enzyme for ATP detection and bioluminescence reporter and imaging applications.

Authors:  Bruce R Branchini; Tara L Southworth; Danielle M Fontaine; Dawn Kohrt; Munya Talukder; Elisa Michelini; Luca Cevenini; Aldo Roda; Martha J Grossel
Journal:  Anal Biochem       Date:  2015-06-04       Impact factor: 3.365

2.  Luciferase does not Alter Metabolism in Cancer Cells.

Authors:  Caroline H Johnson; Timothy S Fisher; Linh T Hoang; Brunhilde H Felding; Gary Siuzdak; Peter J O'Brien
Journal:  Metabolomics       Date:  2014-06-01       Impact factor: 4.290

3.  Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy.

Authors:  Hoon Sim; Kristin Bibee; Samuel Wickline; David Sept
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

Review 4.  In vivo imaging of immune cell trafficking in cancer.

Authors:  Luisa Ottobrini; Cristina Martelli; Daria Lucia Trabattoni; Mario Clerici; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-18       Impact factor: 9.236

5.  Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.

Authors:  Thomas Poeschinger; Anja Renner; Thomas Weber; Werner Scheuer
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

6.  Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies.

Authors:  Jeffry Cutrera; Blake Johnson; Lee Ellis; Shulin Li
Journal:  Cancer Lett       Date:  2012-10-27       Impact factor: 8.679

7.  Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy.

Authors:  Sarah C Jost; Lynne Collins; Sarah Travers; David Piwnica-Worms; Joel R Garbow
Journal:  Mol Imaging       Date:  2009 Sep-Oct       Impact factor: 4.488

8.  Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo.

Authors:  Jessamy C Tiffen; Charles G Bailey; Cynthia Ng; John E J Rasko; Jeff Holst
Journal:  Mol Cancer       Date:  2010-11-22       Impact factor: 27.401

9.  Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer.

Authors:  V P Baklaushev; A Kilpeläinen; S Petkov; M A Abakumov; N F Grinenko; G M Yusubalieva; A A Latanova; I L Gubskiy; F G Zabozlaev; E S Starodubova; T O Abakumova; M G Isaguliants; V P Chekhonin
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

10.  Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.

Authors:  Chloe C Milsom; Christina R Lee; Christina Hackl; Shan Man; Robert S Kerbel
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.